Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    B7-33

    Other

    Status
    Preclinical, , not approved for human use
    Evidence

    Not graded on a research bench yet

    B7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.

    Reviewed

    01Overview

    What B7-33 is

    The compound was developed by Mohammed Akhter Hossain, Ross Bathgate, and colleagues at the Florey Institute of Neuroscience and Mental Health and Monash University in Australia as part of a medicinal chemistry program seeking to capture the therapeutic benefits of native H2 relaxin in a simpler, synthetically accessible molecule that could be manufactured at scale and developed into a clinical drug. Native H2 relaxin itself is a two-chain, disulfide-linked protein of roughly 6 kDa that is difficult and expensive to produce by recombinant methods; the first attempt at translating relaxin therapy into a drug was serelaxin (recombinant human H2 relaxin), which advanced into large Phase 3 trials for acute heart failure before failing to meet its primary endpoint in the RELAX-AHF-2 trial and being discontinued as a heart failure drug candidate. B7-33 represents a second-generation approach — if the two-chain recombinant protein is commercially impractical and clinically disappointing at the specific dose and formulation tested, can a simpler single-chain analog with favorable PK properties capture enough of the relaxin activity to be useful? The published work from the Bathgate group and collaborators ([Hossain et al., 2016]; [Samuel et al., 2017]) shows that B7-33 activates RXFP1 with a biased agonism profile favoring the ERK1/2-pERK signaling pathway over the classical cAMP pathway activated by full-length H2 relaxin, and this biased signaling is associated with preservation of the anti-fibrotic and cardioprotective effects of relaxin while potentially reducing some of the off-target effects associated with full relaxin signaling. In preclinical cardiovascular disease models, B7-33 administration reduces cardiac fibrosis, improves diastolic and systolic function in heart failure models, reduces kidney fibrosis in chronic kidney disease models, and produces hemodynamic effects similar to full-length relaxin but at a simpler molecular scaffold. The specific indication space where B7-33 is being evaluated for potential development includes acute heart failure (where serelaxin failed but where the relaxin mechanism still has strong biological rationale), chronic heart failure with preserved or reduced ejection fraction, diabetic cardiomyopathy, chronic kidney disease with cardio-renal syndrome, and broader anti-fibrotic applications in organ fibrosis. The practical reality in April 2026 is that B7-33 remains a preclinical research peptide with no approved human use, no registered clinical trials at the Phase 1 level or later, and no pharmaceutical-grade supply. It is sold by research-chemical peptide vendors with the standard "for research purposes only" framing, and a small but dedicated biohacker community has experimented with it primarily in cardiometabolic and anti-fibrotic protocols. The evidence base for self-experimentation is limited to extrapolation from rodent studies of B7-33 specifically plus the broader relaxin literature including the failed serelaxin program. This entry covers the mechanism of biased RXFP1 agonism in detail, the preclinical pharmacology across cardiovascular, renal, and fibrotic disease models, the context provided by the serelaxin clinical program and what its failure does and does not tell us about relaxin biology in humans, the theoretical and practical concerns with self-administration of an unvalidated peptide targeting a significant cardiovascular pathway, how B7-33 relates to other cardioprotective and anti-fibrotic interventions like BPC-157, TB-500, Humanin, and prescribed cardiometabolic medications, and what disciplined thinking about this compound looks like for someone considering it seriously. The core takeaway is that B7-33 rests on a mechanism with strong biological rationale but an uncertain clinical track record from the parent class, represents real pharmacological sophistication in its biased agonism profile, and has a substantial gap between promising preclinical data and validated human use.

    How it works

    B7-33's mechanism centers on selective, biased activation of the relaxin family peptide receptor 1 (RXFP1), a G-protein-coupled receptor that responds physiologically to the peptide hormone H2 relaxin. RXFP1 is expressed on cardiac fibroblasts, cardiomyocytes, vascular smooth muscle cells, vascular endothelial cells, renal fibroblasts and mesangial cells, hepatic stellate cells, pulmonary fibroblasts, and several other tissue contexts where relaxin signaling modulates fibrotic and vasodilatory responses. Full-length H2 relaxin activates RXFP1 through a two-step mechanism: an initial high-affinity binding to the receptor's ectodomain, followed by engagement of the transmembrane domain that triggers G-protein coupling. Activated RXFP1 couples primarily to Gs (stimulating adenylyl cyclase and cAMP production) and secondarily to other G-protein pathways, with downstream activation of PKA, ERK1/2, PI3K/Akt, and NO synthesis through activation of eNOS. The downstream signaling produces multiple biological effects: vasodilation through NO-mediated smooth muscle relaxation; anti-fibrotic effects through ERK1/2-mediated inhibition of fibroblast proliferation and collagen deposition; anti-inflammatory effects through NF-kB pathway modulation; and cardioprotective effects through a combination of hemodynamic, anti-fibrotic, and metabolic mechanisms. B7-33 is described as a biased agonist of RXFP1 because its activation profile favors the ERK1/2 pathway over the cAMP pathway, producing selective engagement of the signaling arm most closely associated with the anti-fibrotic effects of relaxin while reducing engagement of the cAMP-mediated effects ([Hossain et al., 2016]). Biased agonism is a relatively recent concept in GPCR pharmacology that emerged from recognition that different ligands binding the same receptor can produce distinct downstream signaling profiles by stabilizing different receptor conformations, and that these different signaling biases can produce different therapeutic profiles with different side effect patterns. The theoretical advantage of a biased agonist is that it can capture the desired signaling arm without engaging off-target signaling, potentially producing better therapeutic index. For relaxin, the ERK1/2 bias that B7-33 shows is thought to preserve the anti-fibrotic cardioprotective effects while reducing contributions from signaling pathways that may not be therapeutically relevant or may contribute to adverse effects. The structural basis for B7-33's biased agonism relates to its design as a single-chain 26-amino-acid peptide that retains the critical receptor-binding residues of the H2 relaxin B-chain but lacks the disulfide bonds and A-chain components that contribute to the full-length hormone's complete signaling profile. The peptide engages RXFP1's transmembrane activation domain preferentially over the ectodomain, producing the altered signaling bias observed. Downstream of biased RXFP1 activation, B7-33 produces functional effects that have been characterized in multiple preclinical models. In cardiac fibroblasts, B7-33 reduces TGF-beta-induced differentiation into myofibroblasts, reduces collagen I and III synthesis, reduces expression of fibrotic markers including alpha-smooth muscle actin and connective tissue growth factor, and increases matrix metalloproteinase activity responsible for degrading existing extracellular matrix. In whole-animal models of cardiac hypertrophy and fibrosis (angiotensin II infusion, pressure overload from aortic constriction, isoproterenol-induced cardiomyopathy), B7-33 administration reduces cardiac fibrosis on histological analysis, reduces expression of fibrotic genes in cardiac tissue, preserves or improves cardiac function on echocardiographic assessment, and produces favorable changes in cardiac hemodynamics ([Samuel et al., 2017]). In renal disease models, similar anti-fibrotic effects have been demonstrated in kidney tissue with preserved renal function and reduced markers of glomerular and tubulointerstitial fibrosis. Beyond the core cardio-renal effects, B7-33 has been examined for effects on pulmonary fibrosis, hepatic fibrosis, skin fibrosis, and other fibrotic conditions where the underlying biology involves fibroblast activation, collagen deposition, and extracellular matrix remodeling. The consistency of anti-fibrotic effects across tissues supports the mechanistic model that biased RXFP1 activation produces fibroblast-level effects that translate to tissue-level anti-fibrotic phenotype. The mechanism has important qualifications. First, the functional selectivity of biased agonism in real-world therapeutic contexts is not always as clean as cellular assays suggest, and biased agonists can produce different effects across different tissues depending on receptor expression patterns, coupling partner availability, and context-specific signaling architecture. Whether B7-33's biased profile translates to a cleaner therapeutic window in humans is an empirical question that has not been answered. Second, the translation from preclinical anti-fibrotic efficacy to clinical benefit in fibrotic diseases has been historically difficult; many compounds with anti-fibrotic activity in rodent models have failed in human clinical trials because human fibrosis is driven by complex, multi-pathway processes that may not respond to single-target intervention. Third, the pharmacokinetics of a 26-amino-acid peptide include the usual issues with short peptide half-life, susceptibility to proteolytic degradation, limited oral bioavailability, and need for injection-based delivery that limit its clinical utility for chronic conditions. B7-33 administered by injection has a plasma half-life of approximately several minutes to an hour depending on species and assay, which is short enough to require either continuous infusion (as was done for serelaxin in acute heart failure trials) or frequent repeat dosing for sustained effect. These PK limitations are real and have contributed to the challenges of relaxin-class drug development.

    Benefits listed

    • Anti-fibrotic effects
    • Improved tissue flexibility
    • Cardiovascular protection
    • Enhanced collagen remodeling
    Show 1 moreShow less
    • Potential fertility support

    02Research

    Free with email

    What the research shows

    No research bench grades B7-33 yet. Benches compare compounds people pair, with the evidence for each.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    B7-33 side effects and interactions

    Side effects

    Not in our record

    Our record lists no side effects for B7-33. That means none are recorded here, not that there are none. The Research section has the written safety notes.

    Who should not use it

    Contraindications

    B7-33's mechanism as a vasodilatory and anti-fibrotic peptide creates a specific contraindication profile reflecting cardiovascular, renal, reproductive, and interaction concerns. Acute cardiovascular instability is an absolute contraindication. Recent myocardial infarction (within 6 weeks), unstable angina, cardiogenic shock, severe aortic stenosis, hypertrophic cardiomyopathy with outflow obstruction, or significant uncorrected cardiac arrhythmias should not be exposed to vasodilatory therapy without intensive care settings. Decompensated heart failure requires active medical management and is not an appropriate context for adding research-chemical peptides. Baseline hypotension (systolic blood pressure below 100 mmHg consistently, or symptomatic orthostatic hypotension) is a relative to absolute contraindication because B7-33's vasodilatory effects would be expected to produce symptomatic hypotension at therapeutic doses. Users with low baseline blood pressure should address volume status and consider whether B7-33 is an appropriate experimental choice. Volume depletion from recent diuresis, dehydration, or dietary restriction warrants replenishment before initiating a cycle. Severe renal disease (eGFR below 30 mL/min/1.73m², advanced chronic kidney disease, or acute kidney injury) is a relative to absolute contraindication because altered renal hemodynamics from RXFP1 activation could destabilize tenuous renal function. Patients with significant renal dysfunction should consult nephrology before any experimental intervention. Pregnancy is a nuanced contraindication. Relaxin is a naturally pregnancy-associated hormone, and exogenous RXFP1 activation during pregnancy could theoretically amplify normal pregnancy physiology (systemic vasodilation, cardiovascular changes, joint laxity) in ways that may not be beneficial. The safety of pharmacologic relaxin-class therapy during pregnancy has not been established. Self-administered B7-33 is not appropriate during pregnancy. Breastfeeding is similarly contraindicated because peptide transfer to breast milk and effects on neonatal physiology are uncharacterized. Women trying to conceive should discontinue B7-33 at least 2-4 weeks before attempting conception. Children and adolescents should not use B7-33 because effects on growth, development, and cardiovascular maturation during this life stage are uncharacterized. Active cancer is a relative contraindication because relaxin signaling has been implicated in some tumor biology in complex ways, with RXFP1 expression on some cancer cells and effects on tumor angiogenesis and metastasis that are not fully characterized. Users with cancer history should consult with oncology before use. Severe autoimmune disease on systemic immunomodulatory therapy is a relative contraindication because effects on immune signaling and inflammatory cascades are uncharacterized. Users with rheumatoid arthritis, lupus, inflammatory bowel disease, or other significant autoimmune conditions should discuss with their specialist. Severe hepatic impairment warrants caution because peptide clearance may be altered, though peptides are typically less dependent on hepatic metabolism than small molecules. Bleeding disorders or active anticoagulation are relative contraindications for any injected therapy because of injection-site bleeding risk, not absolute contraindications. Users on warfarin, direct oral anticoagulants, or antiplatelet therapy should apply pressure after injection and watch for persistent bleeding. Known hypersensitivity to peptide products or to any component of the preparation (including bacteriostatic water preservative) is an absolute contraindication. Drug-drug interactions are characterized primarily theoretically because no human interaction studies of B7-33 exist. Theoretical concerns include: antihypertensive medications (ACE inhibitors, ARBs, beta blockers, calcium channel blockers, alpha blockers, diuretics) where additive hypotensive effects could produce symptomatic hypotension; diuretics in particular where volume depletion combined with vasodilation could be problematic; other vasodilators (nitrates, hydralazine, sildenafil and other PDE5 inhibitors) for similar reasons; immunosuppressants where effects on inflammatory signaling could interact with immunomodulation; PDE5 inhibitors for erectile dysfunction where combined vasodilatory effects could produce significant hypotension; and systemic corticosteroids where effects on tissue remodeling could interact with anti-fibrotic effects. Users on complex cardiovascular regimens should discuss B7-33 with their cardiologist and pharmacist before use. NSAIDs and other medications that affect renal hemodynamics could interact with B7-33's renal effects and warrant attention. The final and most important contraindication is the absence of adequate clinical oversight. Self-experimentation with an unvalidated cardiovascular peptide without a knowledgeable physician who can monitor response and evaluate adverse events does not meet the minimum safety standard for B7-33's risk profile. This is not a specific medical contraindication — it is an infrastructure contraindication that applies regardless of individual health status. Finding a physician with expertise in experimental cardiovascular pharmacology is difficult but possible; the effort is worth more than the peptide itself.

    Interactions

    2 pairings in our record: 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • BPC-157

      Compatible

      Complementary tissue repair — B7-33 for fibrosis, BPC-157 for healing

    • GHK-Cu

      Synergistic

      Both promote tissue remodeling and collagen regulation

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    B7-33 dosage and protocols

    Dose range
    500-4000 mcg subcutaneous per injection (community/self-report research doses; most commonly ~1000 mcg / 1 mg once daily). No validated human dose exists - all figures are empirical extrapolations from rodent pharmacology.
    Dosing
    Once daily or every other day, subcutaneous (community practice only). B7-33 has a very short half-life; no validated human dosing schedule exists.

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • How often and how long
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes
    • Stacking notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    B7-33 prices

    1 listing from 1 vendor, opening in the Featured order.

    Pack prices
    $42.80
    Lowest per mg
    $4.28/mg
    Vendors
    1
    Listings
    1 (vial)

    Prices as the vendors list them, last recorded 14 September 2026.

    Form
    Sort
    B7-33 listings, in Featured order
    VendorProductPriceBuy

    B7-33 10mg

    vial, 1 vial

    In stock

    $4.28/mg

    $42.80

    Lowest per mg
    Buy B7-33 10mg at Limitless Biochem EU
    Vendors selling B7-33(1: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Review B7-33

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with B7-33.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C125H180N30O35S4
    Molecular mass
    2986.58 g/mol
    CAS number
    1421043-98-3
    IUPAC name
    Ac-Asp-Val-Ala-His-Phe-Ala-Ala-Val-Gln-Pro-Cys-Glu-Thr-Gly-Cys-Ser-Arg-Ile-Pro-Ile-Phe-Lys-Asp-Cys-Gly-Pro-Gly-Lys-NH2
    Amino acid sequence
    VIKLSGRELVRAQIAISGMSTWSKRSL - single-chain linear peptide, 27 residues. B7-33 is a derivative of the human H2 relaxin B-chain: the native B-chain (B1-29) is truncated by 6 N-terminal residues and extended at the C-terminus by KRSL (spanning relaxin B-chain positions B7-B33), and the two native B-chain cysteines (B11 and B23) are replaced with isosteric serine to prevent dimerization/aggregation. It therefore contains no cysteines and no disulfide bonds (Hossain et al., Chemical Science 2016).
    Half-life
    In vitro serum-stability half-life is approximately 6 minutes; B7-33 is rapidly degraded (a lipidated analog extended this to ~60 minutes in the same assay). Human in vivo pharmacokinetics are unpublished, and rapid clearance is expected for a small linear peptide (Praveen et al. 2023, PMID 37047588).

    08Questions

    Frequently asked questions

    What is B7-33 and how is it related to relaxin?

    B7-33 is a single-chain, 27-amino-acid synthetic peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the anti-fibrotic and cardioprotective effects of endogenous human H2 relaxin in a simpler, synthetically accessible form. It is a truncated, C-terminally extended derivative of the H2 relaxin B-chain (residues B7-B33) in which the two native B-chain cysteines were replaced with serine to prevent dimerization, so it carries no disulfide bonds. It was developed by the Bathgate and Hossain laboratories at the Florey Institute and Monash University in Australia. Compared to full-length H2 relaxin, B7-33 exhibits biased agonism at RXFP1, preferentially activating the ERK1/2 (pERK) signaling pathway over the cAMP pathway (Hossain et al., 2016).

    Has B7-33 been tested in humans?

    No. As of April 2026, no Phase 1 or later clinical trials of B7-33 have been published, no IND applications have been publicly disclosed, and no registered trials appear on ClinicalTrials.gov under the B7-33 name. Human data on relaxin-class therapy come primarily from the serelaxin (recombinant H2 relaxin) development program, which failed in Phase 3 for acute heart failure despite promising Phase 2 results.

    What is biased agonism and why does it matter for B7-33?

    Biased agonism is when different ligands binding the same receptor produce different downstream signaling profiles by stabilizing different receptor conformations. B7-33's biased activation of RXFP1 favors the ERK1/2 pathway (associated with anti-fibrotic effects) over the cAMP pathway (associated with some of relaxin's other effects). The theoretical advantage is that biased agonism can capture desired signaling while reducing off-target effects, potentially producing a better therapeutic index than full agonism.

    What conditions is B7-33 potentially useful for?

    Preclinical research has examined B7-33 in cardiac fibrosis and heart failure models, renal fibrosis and chronic kidney disease, pulmonary fibrosis, hepatic fibrosis, and other organ fibrotic conditions. The consistent preclinical signature is reduced fibrosis and preserved or improved organ function. Clinical translation for specific indications has not occurred. Self-experimenters typically use B7-33 for cardioprotective and anti-fibrotic purposes, though without clinical validation of these applications.

    What dose of B7-33 do people typically use?

    Self-report community doses range from 500-4000 micrograms per injection subcutaneously, typically once daily or every other day. Beginners usually start at 500-1000 mcg for 4-6 week cycles; intermediate users run 1000-2000 mcg for 6-10 weeks; advanced users go up to 2000-4000 mcg. These doses are empirical extrapolations from rodent studies and have no clinical validation in humans.

    Why did serelaxin fail in clinical trials? Does that mean B7-33 will fail?

    Serelaxin (recombinant H2 relaxin) failed to meet its primary endpoint in the RELAX-AHF-2 Phase 3 trial for acute heart failure, despite promising Phase 2 results. The reasons are debated - possibilities include unfavorable trial design, inadequate dose or duration, patient population issues, or fundamental biology differences between rodents and humans. The serelaxin failure does not automatically predict B7-33 failure, because B7-33 differs in its biased agonism profile, smaller size, and different PK. However, it establishes that positive preclinical data does not guarantee clinical efficacy for relaxin-class therapy.

    What are the main side effects of B7-33?

    Human side effects are undocumented for B7-33 specifically because no clinical trials exist. Based on mechanism and the serelaxin clinical experience, the most predictable effects are hypotension (vasodilatory effects) and occasionally worsened renal function. Theoretical concerns include effects on reproductive function, joint laxity (since relaxin naturally increases joint laxity), and effects on tissues where physiologic fibrosis is protective (acute wound healing, tissue repair). Injection-site reactions are common with any subcutaneous peptide.

    Can I combine B7-33 with my heart failure medications?

    Any combination with prescribed cardiovascular medications should be discussed with your cardiologist before starting. B7-33 has theoretical interactions with ACE inhibitors, ARBs, beta blockers, calcium channel blockers, and diuretics through additive hemodynamic effects. Users should not substitute B7-33 for validated heart failure medications, should not discontinue prescribed medications to use B7-33, and should maintain regular cardiology follow-up if they add experimental compounds to established treatment.

    Is B7-33 safe if I have high blood pressure?

    B7-33 produces vasodilation and could theoretically help lower blood pressure, but uncontrolled blood pressure requires established medical management, not experimental peptides. Users with well-controlled hypertension on stable regimens may be able to use B7-33 cautiously with close blood pressure monitoring and medication adjustment as needed, but this should be coordinated with their physician. Users with uncontrolled or labile blood pressure should stabilize control before considering experimental interventions.

    Is B7-33 worth the cost given the limited evidence?

    The decision depends on individual circumstances - risk tolerance, financial resources, existing cardiovascular risk factors, access to clinical support, and willingness to experiment with an unvalidated compound. For someone with specific cardiovascular risk factors or early cardiometabolic disease, adequate clinical support, optimized medical therapy and lifestyle, and resources to test the compound in a structured way, B7-33 represents a reasonable experimental option alongside validated approaches. For someone with advanced cardiovascular disease, limited clinical support, or unstable medical circumstances, self-treatment with a research-chemical peptide is not an adequate approach and professional care should be the priority.

    How many vendors sell B7-33, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list B7-33 (1 listing). Among BodyHackGuide's B7-33 listings recorded as in stock with a milligram count, the lowest price per milligram is $4.28/mg at Limitless Biochem EU and the median is $4.28/mg. The B7-33 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a B7-33 listing is dated 14 September 2026.

    Which vendors have third-party COAs for B7-33 on file at BodyHackGuide?

    BodyHackGuide holds no third-party certificate records for B7-33. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free